Roche Obesity Pipeline: CT-388, Petrelintide, and the Carmot Reset
Roche matters because it has enough scale to become a major obesity player fast if its current assets mature the right way.
Why this matters
Roche matters because obesity is one of the few categories where a big company can still buy or build relevance quickly through the right asset mix.
Current read
CT-388 is the cleaner incretin story. Petrelintide broadens Roche's position through amylin-pathway exposure. The pipeline is credible, but not yet defining the market.
Primary query
roche obesity pipeline
Page type
Company Tracker
Lead read
CT-388
Stage mix
2 phase 2
Pipeline facts for search and AI answers
What this company tracker page answers
Primary query
roche obesity pipeline
The page is built to answer this pipeline query directly before routing readers deeper.
Tracker type
Company Tracker
This page tracks one company's obesity pipeline and how those assets fit together strategically.
Lead read
CT-388
CT-388 is the cleaner incretin story. Petrelintide broadens Roche's position through amylin-pathway exposure. The pipeline is credible, but not yet defining the market.
Stage mix
2 phase 2
FormBlends separates early pipeline interest from late-stage, filed, and approved assets.
Direct answer
What is it?
CT-388 is a phase 2 program from Roche/Carmot built around GLP-1/GIP.
Why does it matter?
Roche matters because it has enough scale to become a major obesity player fast if its current assets mature the right way.
What should you read next?
What we know right now
Roche matters because it has enough scale to become a major obesity player fast if its current assets mature the right way.
CT-388 is the cleaner incretin story. Petrelintide broadens Roche's position through amylin-pathway exposure. The pipeline is credible, but not yet defining the market.
Right now this page is anchored by CT-388, Petrelintide, which is why the lane feels more concrete than a generic trend piece.
What is still uncertain
This topic is still a mid-stage read. There is enough movement to matter, but not enough to treat the whole lane as settled.
The next milestone is stronger proof-of-concept data that shows which names deserve to graduate into serious launch conversations.
The biggest mistake in obesity pipeline content is treating strategic interest like commercial inevitability. This page is built to keep those two things separate.
What FormBlends is watching
- Whether Roche turns CT-388 into a true top-tier commercial priority
- How petrelintide fits into a broader satiety and combination strategy
- Whether Roche moves from credible participant to real market threat
Decision path
How should I interpret Roche Obesity Pipeline: CT-388, Petrelintide, and the Carmot Reset?
This pipeline page is a decision aid for market context, not a patient access page. Use it to understand which mechanisms, companies, and trial stages are worth watching before comparing anything to available care.
- Topic
- roche obesity pipeline
- Type
- Company Tracker
- Tracked names
- 2
- Stage mix
- 2 phase 2
Step 1
Check maturity
This topic is still a mid-stage read. There is enough movement to matter, but not enough to treat the whole lane as settled.
Step 2
Watch the next signal
The next milestone is stronger proof-of-concept data that shows which names deserve to graduate into serious launch conversations.
Open status hubStep 3
Compare to care today
Pipeline excitement should be separated from treatment decisions that require provider review, a legally available medication, and follow-up.
View current optionsHow this lane stacks up right now
A quick read on the compounds carrying the most weight on this page.
| Compound | Developer | Mechanism | Stage | Next step |
|---|---|---|---|---|
| CT-388 | Roche/Carmot | GLP-1/GIP | Phase 2 | Read status page |
| Petrelintide | Roche/Zealand | Amylin | Phase 2 | Read status page |
Featured compounds in this lane
These are the names currently doing the real work in this part of the pipeline.
Related comparisons
CT-388 vs VK2735: Roche's Dual Agonist Entry vs Viking's Lead Asset
VK2735 is ahead. CT-388 is still more of a watchlist asset than a category-defining one. That can change, but today this is mainly a comparison between a late-stage contender and a promising chaser.
Cagrilintide vs Petrelintide: Which Amylin Pathway Asset Looks Cleaner?
Cagrilintide has the stronger ecosystem. Petrelintide may have the cleaner identity. If you think the amylin pathway wins mainly through big-company combos, cagrilintide matters more. If you think the market may reward a more distinct amylin story, petrelintide is the better watch.
FormBlends separates trial-stage tracking from actual patient availability.
Late-stage, filed, and approved assets are treated differently from early exploratory programs.
This page is meant to answer the query fast, then route readers into compound, status, and comparison pages for deeper analysis.